Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine vs Escitalopram for Co-Morbid Depression and Alcoholism
NCT00368862Phase 4Completed
- Sponsor
- Finnish Institute for Health and Welfare
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of memantine in major depressive disorder (MDD) and alcohol dependence, sponsored by Finnish Institute for Health and Welfare. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 26 weeks and Hamilton Anxiety Rating Scale at 26 weeks. Started Dec 2005; status: completed.
02
Drugs
memantine
03
Conditions
major depressive disorder (MDD)alcohol dependence
Beyond the preview
Go deeper on NCT00368862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368862.